Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19
Treatment with BEB was not inferior to NR with respect to 30-day all-cause hospitalization or death. The risk of secondary outcomes was not different for patients treated with BEB compared to NR.
Authors
- Russell Nichols (ORCID: https://orcid.org/0000-0001-7771-7366)
- Jennifer M. Alyea
- K. Arnold Chan (ORCID: https://orcid.org/0000-0001-8161-1986)
- Baojin Zhu (ORCID: https://orcid.org/0000-0003-4462-1856)
- Christopher G. Rowan (ORCID: https://orcid.org/0000-0002-4318-2970)
- Sengwee Toh (ORCID: https://orcid.org/0000-0002-5160-0810)
- Elsie Grace
- Neil Dhopeshwarkar (ORCID: https://orcid.org/0000-0001-6305-256X)
Institutions
- Harvard University (US)
- Eli Lilly (United States) (US)
- Harvard Pilgrim Health Care (US)
- TriNetX (United States) (US)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1007/s41030-024-00284-w
- Citations
- 1
- Primary Topic
- Adrenal Hormones and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- Eli Lilly and Company